Sorrento Therapeutics, Inc. Form SC 13G May 23, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. ___)*

Sorrento Therapeutics, Inc. (Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

83587F202 (CUSIP Number)

May 15, 2014

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 		•

CUSIP No. 83587F202		S	Page CHEDULE 13G	age 2 of 13	3
1			REPORTING PERSON OR FIFICATION NO. OF ABOVE PERSON		
2	CHECK	THE	tal III, LP E APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) c (b) x
3	SEC US	E Or	NL Y		
4	CITIZEI	NSH	IP OR PLACE OF ORGANIZATION		
NUMBER SHAF BENEFIC OWN BY EA	RES TALLY ED ACH	re 5 6 7	SOLE VOTING POWER 1,763,500 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER		
REPORTII PERSON WITH	ON	8	1,763,500 SHARED DISPOSITIVE POWER 0		
9	AGGRE	GAT	U TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PER	RSON	
10		ВОХ	ee Item 4) X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	.IN	o
11	PERCE	NT O	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
12	6.3% TYPE O	F RE	EPORTING PERSON		
	PN				

CUSIP No. 83587F202		S	Page CHEDULE 13G	ge 3 of 1.	3
1			REPORTING PERSON OR FIFICATION NO. OF ABOVE PERSON		
2	_	THE	tal Partners III, LP E APPROPRIATE BOX IF A MEMBER OF A GROUP NLY		(a) o (b) x
4	CITIZEI	NSH	IP OR PLACE OF ORGANIZATION		
NUMBER SHAI BENEFIC OWN BY EA REPOR PERS WIT	RES CIALLY ED ACH TING ON	e 5 6 7 8	SOLE VOTING POWER 1,763,500 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 1,763,500 SHARED DISPOSITIVE POWER 0		
9	AGGRE	EGAT	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PER	RSON	
10		ВО	ee Item 4) X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	IN	o
11	PERCE	NT O	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
12		F RE	EPORTING PERSON		
	PN				

CUSIP No. 83587F202		S	SCHEDULE 13G	nge 4 of 1	3	
1			REPORTING PERSON OR TIFICATION NO. OF ABOVE PERSON			
2	Aisling Capital Partners III LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
3	SEC US	E Ol	NLY			
4	CITIZEI	NSH	IP OR PLACE OF ORGANIZATION			
	Delawar	re 5	SOLE VOTING POWER			
NUMBER SHAF BENEFIC OWN	RES CIALLY	6	1,763,500 SHARED VOTING POWER			
BY EA REPOR PERS	TING	7	SOLE DISPOSITIVE POWER			
WIT		8	1,763,500 SHARED DISPOSITIVE POWER			
9	AGGRE	GAT	0 ΓΕ AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PE	RSON		
10		ВО	ee Item 4) X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	AIN	0	
11	PERCE	NT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
12	6.3% TYPE O	F RI	EPORTING PERSON			
	00					

CUSIP No. 83587F202		S	SCHEDULE 13G	age 5 of 1	3
			REPORTING PERSON OR TIFICATION NO. OF ABOVE PERSON		
	Steve El	ms			
2	CHECK	THI	E APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) o (b) x
3	SEC US	E OI	NLY		
4	CITIZEI	NSH	IP OR PLACE OF ORGANIZATION		
	United S	tates	S		
		5	SOLE VOTING POWER		
NUMBER (SHAR BENEFIC OWN BY EA REPOR' PERS(WIT	EES IALLY ED CH ING ON	678	0 SHARED VOTING POWER 1,763,500 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 1,763,500		
9	AGGRE	GA7	ΓΕ AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PE	RSON	
10		ВО	ee Item 4) X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	AIN	0
11	PERCE	NT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	6.3% TYPE O	F RI	EPORTING PERSON		
	IN				

CUSIP No. 83587F202		S	SCHEDULE 13G	age 6 of 13	
1			REPORTING PERSON OR TIFICATION NO. OF ABOVE PERSON		
	Dennis l	Purce	ell		
2	CHECK	THI	E APPROPRIATE BOX IF A MEMBER OF A GROUP		a) o b) z
3	SEC US	E Ol	NLY		
4	CITIZE	NSH	IIP OR PLACE OF ORGANIZATION		
	United S	States	s		
		5	SOLE VOTING POWER		
NUMBER OF SHARES BENEFICIALLY		6	0 SHARED VOTING POWER		
OWN BY EA			1,763,500		
REPOR	TING	7	SOLE DISPOSITIVE POWER		
PERS WIT			0		
		8	SHARED DISPOSITIVE POWER		
			1,763,500		
9	AGGRE	GA.	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PE	RSON	
	1,763,50	00 (S	See Item 4)		
10	CHECK SHARE		X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	AIN o)
11	PERCE	NT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	6.3%				
12	TYPE C)F RI	EPORTING PERSON		
	IN				

CUSIP No. 83587F202		S	SCHEDULE 13G	age 7 of 13	3	
1			REPORTING PERSON OR TIFICATION NO. OF ABOVE PERSON			
2	Andrew Schiff CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
3	SEC US	E Ol	NLY			
4	CITIZE	NSH	IP OR PLACE OF ORGANIZATION			
	United S	States 5	SOLE VOTING POWER			
NUMBER SHAF BENEFIC OWN	RES CIALLY	6	0 SHARED VOTING POWER 1,763,500			
BY EA REPOR PERS WIT	TING ON	7	SOLE DISPOSITIVE POWER 0			
WII	11	8	SHARED DISPOSITIVE POWER			
9	AGGRE	GAT	1,763,500 ГЕ AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PE	ERSON		
10		ВО	ee Item 4) X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	AIN	o	
11	PERCE	NT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
12	6.3% TYPE O	F RI	EPORTING PERSON			
	IN					

CUSIP No.
83587F202

SCHEDULE 13G

Name of Issuer:

Sorrento Therapeutics, Inc. (the "Issuer")

(b)

Address of Issuer's Principal Executive Offices:
6042 Cornerstone Ct. West, Suite B, San Diego, California 92121

I T E M(a)
Name of Person Filing:
2.

This Schedule 13G (this "Statement") is being filed by the following persons (collectively, the "Reporting Persons"):

(i) Aisling Capital III, LP, a Delaware limited partnership ("Aisling");

- (ii) Aisling Capital Partners III, LP, a Delaware limited partnership ("Aisling Partners" and a general partner of Aisling);
- (iii) Aisling Capital Partners III LLC, a Delaware limited liability company ("Aisling Partners GP" and a general partner of Aisling Partners);

(iv)Mr. Steve Elms ("Mr. Elms" and a managing member of Aisling Partners GP); (v)Mr. Dennis Purcell ("Mr. Purcell" and a managing member of Aisling Partners GP); and (vi)Mr. Andrew Schiff ("Mr. Schiff" and a managing member of Aisling Partners GP).

(b) Address of Principal Business Office, or if None, Residence:

The address of the principal business offices of each of the Reporting Persons is 888 Seventh Avenue, 30th Floor, New York, New York 10106.

(c) Citizenship:

(i)Aisling — a Delaware limited partnership
(ii)Aisling Partners — a Delaware limited partnership
(iii)Aisling Partners GP — a Delaware limited liability company
(iv)Mr. Elms — United States
(v)Mr. Purcell — United States
(vi)Mr. Schiff — United States

(d) Title of Class of Securities:

Common Stock, par value \$0.0001 per share (the "Common Stock").

(e) CUSIP Number:

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13G

83587F202

ITEM 3.	IIF THIS STATEMENT IS WHETHER THE PERSO	S FILED PURSUANT TO §240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK ON FILING IS A:
	(a)	[] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
	(b)	[_] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)
	(c)	[] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C.
		78c)
	(d)	[] Investment company registered under Section 8 of the Investment
		Company Act of 1940 (15 U.S.C. 80a-8)
	(e)	[] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)
	(f)	[] An employee benefit plan or endowment fund in accordance with
		§240.13d-1(b)(1)(ii)(F);

CUSIP No. 83587F202	SCHEDUL	E 13G	Page 9 of 13
	(g)	[] A Parent hold §240.13d-1(b)(1)(ii	ing company or control person in accordance with ()(G):
	(h)		ociations as defined in Section 3(b) of the Federal Deposit
	(i)	[] A church plan	that is excluded from the definition of an investment tion 3(c)(14) of the Investment Company Act of 1940 (15
	(j) (k)		stitution in accordance with \$240.13d-1(b)(1)(ii)(J); ordance with \$240.13d-1(b)(1)(ii)(J).
ITEM 4.	OWNERSHIP		
	(a)	Amount beneficiall	y owned:
		_	ng Persons may be deemed to beneficially own an aggregate of Common Stock.
	(b)	Percent of class:	
			ations made in accordance with Rule 13d-3(d), each of the may be deemed to beneficially own approximately 6.3% of mmon Stock.
		presented in this State outstanding number	ownership of the Common Stock by Reporting Persons atement is based on 27,818,100 shares which is the total r of shares of the Common Stock reported in the Issuer's nent filed with the Securities and Exchange Commission by 15, 2014.
	(c)	Number of shares a	s to which such person has:
		(i), (iii)	Sole power to vote or to direct the vote/Sole power to dispose of or to direct the disposition of:
			Each of Aisling, Aisling Partners and Aisling Partners GP may be deemed to have sole power to direct the voting and disposition of the 1,763,500 shares of Common Stock beneficially owned by Aisling.
		(ii), (iv)	Shared power to vote or to direct the vote/Shared power to dispose of or to direct the disposition of:
			By virtue of the relationships between and among the

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13G

Reporting Persons as described in Item 2, each of Mr. Elms, Mr. Purcell and Mr. Schiff may be deemed to share the power to direct the voting and the disposition of the 1,763,500 shares of Common Stock beneficially owned by Aisling.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

Not Applicable.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ".

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Shares held for the account of Aisling in accordance with their ownership interests in Aisling.

CUSIP No. Page 10 of 13

83587F202 SCHEDULE 13G

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH

ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING

COMPANY.

Not Applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not Applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

Not Applicable.

ITEM 10. CERTIFICATIONS.

Each of the Reporting Persons hereby makes the following certification:

By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with

a nomination under section 240.14a-11.

CUSIP No. Page 11 of 13

83587F202 SCHEDULE 13G

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 23, 2014

AISLING CAPITAL III, LP

By: Aisling Capital Partners III, LP,

As its General Partner

By: Aisling Capital Partners III LLC,

As its General Partner

By: /s/ Dennis Purcell

Name: Dennis Purcell Title: Managing Member

AISLING CAPITAL PARTNERS III, LP

By: Aisling Capital Partners III LLC,

As its General Partner

By: /s/ Dennis Purcell

Name: Dennis Purcell Title: Managing Member

AISLING CAPITAL PARTNERS III LLC

By: /s/ Dennis Purcell

Name: Dennis Purcell Title: Managing Member

STEVE ELMS

By: /s/ Steve Elms

CUSIP No.		Page 12 of 13
83587F202	SCHEDULE 13G	

DENNIS PURCELL

By: /s/ Dennis Purcell

ANDREW SCHIFF

By: /s/ Andrew Schiff

CUSIP No.		Page 13 of 13
83587F202	SCHEDULE 13G	

EXHIBIT INDEX

Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as Exhibit 1. amended.